Mary Strange

Ms. Mary Strange

Magee-Womens Research Institute, Pittsburgh, Pennsylvania, USA
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2005 in Cancer Genetics and Cytogenetics
Verified
Journal Article
Closed access
CWCathy B. Wilcox
Cathy B. Wilcox
BBBora E. Baysal
Bora E. Baysal
HGHolly H. Gallion
Holly H. Gallion
MSMary Strange
Mary Strange
JDJulie A. DeLoia
Julie A. DeLoia

5 March 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
DKDiana L. Kolbe
Diana L. Kolbe
JDJulie A. DeLoia
Julie A. DeLoia
PPPatricia Porter-Gill
Patricia Porter-Gill
MSMary Strange
Mary Strange
HPHanna M. Petrykowska
Hanna M. Petrykowska
LELaura Elnitski
Laura Elnitski
Despite improved outcomes in the past 30 years, less than half of all women diagnosed with epithelial ovarian cancer live five years beyond their diagnosis. Although typically treated as a single disease, epithelial ovarian cancer includes several distinct histological subtypes, such as papillary serous and endometrioid carcinomas. To address whether the morphological differences seen in these carcinomas represent distinct characteristics at the molecular level we analyzed DNA methylation patterns in 11 papillary serous tumors, 9 endometrioid ovarian tumors, 4 normal fallopian tube samples and 6 normal endometrial tissues, plus 8 normal fallopian tube and 4 serous samples from TCGA. For comparison within the endometrioid subtype we added 6 primary uterine endometrioid tumors and 5 endometrioid metastases from uterus to ovary. Data was obtained from 27,578 CpG dinucleotides occurring in or near promoter regions of 14,495 genes. We identified 36 locations with significant increases or decreases in methylation in comparisons of serous tumors and normal fallopian tube samples. Moreover, unsupervised clustering techniques applied to all samples showed three major profiles comprising mostly normal samples, serous tumors, and endometrioid tumors including ovarian, uterine and metastatic origins. The clustering analysis identified 60 differentially methylated sites between the serous group and the normal group. An unrelated set of 25 serous tumors validated the reproducibility of the methylation patterns. In contrast, >1,000 genes were differentially methylated between endometrioid tumors and normal samples. This finding is consistent with a generalized regulatory disruption caused by a methylator phenotype. Through DNA methylation analyses we have identified genes with known roles in ovarian carcinoma etiology, whereas pathway analyses provided biological insight to the role of novel genes. Our finding of differences between serous and endometrioid ovarian tumors indicates that intervention strategies could be developed to specifically address subtypes of epithelial ovarian cancer.

18 January 2022 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
BOBrian Orr
Brian Orr
HMHaider Mahdi
Haider Mahdi
YFYusi Fang
Yusi Fang
MSMary Strange
Mary Strange
IUIbrahim Uygun
Ibrahim Uygun
AVAnda Vlad
Anda Vlad
Purpose: Increased prevalence of cytotoxic T lymphocytes (CTL) in the tumor microenvironment (TME) predicts positive outcomes in patients with epithelial ovarian cancer (EOC), whereas the regulatory T cells (Treg) predict poor outcomes. Guided by the synergistic activity of TLR3 ligands, IFNα, and COX-2 blockers in selectively enhancing CTL-attractants but suppressing Treg-attractants, we tested a novel intraperitoneal chemoimmunotherapy combination (CITC), to assess its tolerability and TME-modulatory impact in patients with recurrent EOC. Patients and Methods: Twelve patients were enrolled in phase I portion of the trial NCT02432378, and treated with intraperitoneal cisplatin, intraperitoneal rintatolimod (dsRNA, TLR3 ligand), and oral celecoxib (COX-2 blocker). Patients in cohorts 2, 3, and 4 also received intraperitoneal IFNα at 2, 6, and 18 million units (MU), respectively. Primary objectives were to evaluate safety, identify phase 2 recommended dose (P2RD), and characterize changes in the immune TME. Peritoneal resident cells and intraperitoneal wash fluid were profiled via NanoString and Meso Scale Discovery (MSD) multiplex assay, respectively. Results: The P2RD of IFNα was 6 MU. Median progression-free survival and overall survival were 8.4 and 30 months, respectively. Longitudinal sampling of the peritoneal cavity via intraperitoneal washes demonstrated local upregulation of IFN-stimulated genes (ISG), including CTL-attracting chemokines (CXCL-9, -10, -11), MHC I/II, perforin, and granzymes. These changes were present 2 days after chemokine modulation and subsided within 1 week. Conclusions: The chemokine-modulating intraperitoneal-CITC is safe, tolerable, and associated with ISG changes that favor CTL chemoattraction and function. This combination (plus DC vaccine) will be tested in a phase II trial. See related commentary by Aranda et al., p. 1993

1 September 2012 in Gynecologic Oncology
Verified
Journal Article
Closed access
JDJulie A. DeLoia
Julie A. DeLoia
NBNikhil Bhagwat
Nikhil Bhagwat
KDKathleen M. Darcy
Kathleen M. Darcy
MSMary Strange
Mary Strange
CTChunquio Tian
Chunquio Tian
LNLaura J. Niedernhofer
Laura J. Niedernhofer

4 November 2015 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
SGShannon Grabosch
Shannon Grabosch
FZFeitianzhi Zeng
Feitianzhi Zeng
LZLixin Zhang
Lixin Zhang
MSMary Strange
Mary Strange
JBJoan Brozick
Joan Brozick
AVAnda Vlad
Anda Vlad

17 November 2022 in Cancers
Verified
Journal Article
Open access
PDF file
AMAdria Suarez Mora
Adria Suarez Mora
MSMary Strange
Mary Strange
YFYusi Fang
Yusi Fang
IUIbrahim Uygun
Ibrahim Uygun
LZLixin Zhang
Lixin Zhang
AVAnda Vlad
Anda Vlad
The immune tumor microenvironment (TME) of epithelial ovarian cancer (EOC) carries both effector and suppressive functions. To define immune correlates of chemotherapy-induced tumor involution, we performed longitudinal evaluation of biomarker expression on serial biological specimens collected during intraperitoneal (IP) platinum-based chemotherapy. Serial biological samples were collected at several time points during IP chemotherapy. RNA from IP fluid cells and tumor tissue was analyzed via NanoString. Meso Scale Discovery (MSD) multiplex assay and ELISA for MUC1 antibodies were performed on plasma and IP fluid. Differentially expressed genes in IP fluid demonstrate an upregulation of B cell function and activation of Th2 immune response along with dampening of Th1 immunity during chemotherapy. MSD analysis of IP fluid and gene expression analysis of tumor tissue revealed activation of Th2 immunity and the complement system. Anti-MUC1 antibodies were detected in IP fluid samples. IP fluid analysis in a secondary cohort also identified chemotherapy-induced B cell function genes. This study shows that serial IP fluid sampling is an effective method to capture changes in the immune TME during chemotherapy and reveals treatment induced changes in B cell function and Th2 immunity.